These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 18349438)

  • 21. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
    Brisson M; Edmunds WJ
    Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.
    Mogasale V; Barendregt J
    Aust N Z J Public Health; 2011 Apr; 35(2):180-6. PubMed ID: 21463417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam.
    Kim SY; Goldie SJ; Salomon JA
    Med Decis Making; 2010; 30(5):E1-E28. PubMed ID: 20729510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
    Broughton EI
    J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.
    Duintjer Tebbens RJ; Thompson KM; Hunink MG; Mazzuchi TA; Lewandowski D; Kurowicka D; Cooke RM
    Med Decis Making; 2008; 28(2):182-200. PubMed ID: 18349438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.
    Mauskopf J; Talbird S; Standaert B
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):357-71. PubMed ID: 22812559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of immunization strategies.
    Ess SM; Szucs TD
    Clin Infect Dis; 2002 Aug; 35(3):294-7. PubMed ID: 12115095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity analysis in economic evaluation: a review of published studies.
    Briggs A; Sculpher M
    Health Econ; 1995; 4(5):355-71. PubMed ID: 8563834
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.